News & Updates

Esaxerenone produces favourable night-time BP-lowering effect in Asians
Esaxerenone produces favourable night-time BP-lowering effect in Asians
24 Jan 2022 byJairia Dela Cruz

The novel highly selective mineralocorticoid receptor blocker esaxerenone holds promise in the treatment of nocturnal hypertension, yielding substantial reductions in night-time blood pressure (BP), especially in Japanese patients with a riser pattern, as well as in N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, according to a post hoc analysis of a phase III study.

Esaxerenone produces favourable night-time BP-lowering effect in Asians
24 Jan 2022
Upper extremity DVT common in COVID-19 despite proper prophylaxis
Upper extremity DVT common in COVID-19 despite proper prophylaxis
21 Jan 2022

About 10 percent of patients with the coronavirus disease 2019 (COVID-19) will suffer from upper extremity deep vein thrombosis despite adequate prophylaxis, a recent study has found.

Upper extremity DVT common in COVID-19 despite proper prophylaxis
21 Jan 2022
Elevated homocysteine level ups mortality risk in hypertensive adults
Elevated homocysteine level ups mortality risk in hypertensive adults
20 Jan 2022

The interaction of hypertension and total plasma homocysteine (tHcy) levels contributes to the risk of all-cause mortality among middle-aged and older adults, a US study has found. In addition, hypertension may boost the ability of elevated tHcy to aggravate this risk.

Elevated homocysteine level ups mortality risk in hypertensive adults
20 Jan 2022